Simon Tate
Director/Board Member bij ELIEM THERAPEUTICS, INC.
Vermogen: - $ op 29-02-2024
Profiel
Simon Nicholas Tate founded Convergence Pharmaceuticals Ltd.
Currently, Mr. Tate is Venture Partner at Bridge Valley Ventures LLP.
Mr. Tate is also on the board of Calchan Ltd.
and Eliem Therapeutics, Inc.
He previously was Vice President & Head-Pain Therapeutic Area at Biogen, Inc. and Director & Chief Scientific Officer at Convergence Pharmaceuticals Ltd.
(a subsidiary of Biogen, Inc.), Managing Director at Intermediate Capital Group Plc and VP-Pain & Epilepsy Discovery Performance Unit at GlaxoSmithKline, Inc.
Simon Nicholas Tate received a graduate degree from the University Of Dundee.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
-.--% | 18-05-2023 | 0 ( -.--% ) | - $ | 29-02-2024 |
Actieve functies van Simon Tate
Bedrijven | Functie | Begin |
---|---|---|
ELIEM THERAPEUTICS, INC. | Director/Board Member | 01-02-2019 |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Private Equity Investor | - |
Eerdere bekende functies van Simon Tate
Bedrijven | Functie | Einde |
---|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Founder | 12-04-2018 |
INTERMEDIATE CAPITAL GROUP PLC | Corporate Officer/Principal | - |
Calchan Ltd.
Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
BIOGEN INC. | Corporate Officer/Principal | - |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Opleiding van Simon Tate
University Of Dundee | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
BIOGEN INC. | Health Technology |
INTERMEDIATE CAPITAL GROUP PLC | Finance |
ELIEM THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Calchan Holdings Ltd.
Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Calchan Ltd.
Calchan Ltd. BiotechnologyHealth Technology Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Finance |